what's in it for you?
new/era/mabs GmbH is a privately financed biotech company with a proprietary technology platform for the generation of monoclonal and recombinant antibodies for use in research, diagnostic or therapeutic applications.
We provide high-end antibody discovery workflows four times faster than conventional state-of-the-art processes. The platform core component is selma - a highly flexible sorting process for antibody-producing cells based on novel transgenic fusion cell lines.
We offer the customized generation and production of mouse, camelid, and human antibodies for various in vitro and in vivo applications. We permanently expand our R&D segment with next-generation platform improvements and secure the platform approach with different patent families.
Founded in 2014 as an university spin-off located at the Potsdam Science Park the company is embedded in a vibrant scientific environment.
Are you ready to enter a new era of antibody generation?get in touch
our groundbreaking technology
Antibodies are wonderful and reliable tools but the generation so far is tedious and resource intensive. Selecting suitable antibodies is highly complex. When using selma as selection tool you can absolutely rely on having a fast, efficient and highly flexible approach to select your desired antibody producing cell.learn more
murine monoclonal antibodies
The induction of specific antibody responses in mice is performed by immunizing the antigen of choice. To increase the efficacy of this process we developed a hyper-immunization protocol based on viral carrier proteins. In combination with selma as selection tool we provide a high end solution for the discovery of antibody producing hybridoma cells 4times faster than with conventional methods.learn more
human monoclonal antibodies
We can provide a simple and reliable workflow for human monoclonal antibodies too. Human B cells are specifically activated by our in house developed in vitro immunization (IVI) approach. For the antigen specific immunisation we use our viral based carriers or customized antigens. How do we select the desired cells? selma is our universal secret.learn more
camelid recombinant antibodies
Camelid antibodies were spotlighted in the past due to their exclusive properties such as a high temperature stability which would allow workflows without needing a cool chain. This is a very interesting feature for in vitro diagnostic applications. We can provide the complete workflow for the generation of either variable heavy chain antibody fragments (15 kDa) or full length heavy chain only antibodies (90 kDa) for the establishment of a specific test environment. For identification we use our in house naive camelid library or we create customized immune libraries. Also in this case the selection of antibody producing mammalian cells is realised with selma.learn more
published in nature
A novel selection strategy for antibody producing hybridoma cells based on a new transgenic fusion cell line.read article
published in Science
In this Science webinar, Katja Hanack demonstrates that
greatly simplifies and accelerates flow cytometric antibody characterization.
After a free registration you can start the recording at 23:17 min.view webinar